about
Skin symptoms as diagnostic clue for autoinflammatory diseases.Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy.Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients.Eosinophil-cationic protein - a novel liquid prognostic biomarker in melanomaEffective anti-programmed death-1 therapy in a SUFU-mutated patient with Gorlin-Goltz syndromeBlood Eosinophilia is an on-Treatment Biomarker in Patients with Solid Tumors Undergoing Dendritic Cell Vaccination with Autologous Tumor-RNASenescence markers: Predictive for response to checkpoint inhibitorsCheckpoint inhibitor-induced eosinophilic fasciitis following high eosinophilia associated with complete responseMyositis and neuromuscular side-effects induced by immune checkpoint inhibitors
P50
Q37644622-BAE21829-068E-4751-9E10-11C027645572Q38995643-B0D5CA04-B194-4607-B2A6-B7B9221986E1Q55496359-B51F3BE1-F888-49BA-A52E-A749245BC859Q64119230-A8251B0E-DAF8-4073-B851-5A3D1A279070Q88231900-E64C80FB-2ECF-4C94-A064-CEBECE884E88Q89978064-3E673B3D-605F-4B65-9AF3-E09BD99A4419Q91172519-9C47BFB9-9AEA-4B98-A77F-E3727FE6039BQ91771826-9881F1F9-0DA5-4CAF-B57A-393BCC643EA4Q93213787-676F4BA2-EF89-4459-90B4-75D9F91B1BB9
P50
description
researcher
@en
name
A Moreira
@en
type
label
A Moreira
@en
prefLabel
A Moreira
@en
P108
P31
P496
0000-0002-5244-9286